SCHEMBL1741887

SCHEMBL1741887

Cc1cccc(NC(=N)NC(=N)N)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.59
HSD17B10 Q99714 1/20 0.51
SIGMAR1 Q99720 2/20 0.51
GRIN2D O15399 1/20 0.51
GRIN3B O60391 1/20 0.51
GRIN1 Q05586 1/20 0.51
GRIN2A Q12879 1/20 0.51
GRIN2B Q13224 1/20 0.51
GRIN2C Q14957 1/20 0.51
GRIN3A Q8TCU5 1/20 0.51
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
MAPT P10636 2/20 0.47
ALDH1A1 P00352 1/20 0.47
GAA P10253 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
CYP2D6 P10635 2/20 0.47
POLB P06746 1/20 0.47
CRHBP P24387 1/20 0.47
CRHR2 Q13324 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28340523 0.98 CYP1A2 (0.57) CYP1A2HSD17B10SIGMAR1GRIN2DGRIN3B
SCHEMBL19136056 0.97 CYP1A2 (0.56) CYP1A2HSD17B10SIGMAR1GRIN2DGRIN3B
SCHEMBL1740852 0.85 CYP1A2 (0.67) CYP1A2HSD17B10SIGMAR1GRIN2DGRIN3B
SCHEMBL6422898 0.85 HSD17B10 (0.62) CYP1A2HSD17B10SIGMAR1GRIN2DGRIN3B
SCHEMBL27500570 0.82 GAA (0.46) CYP1A2KMT2AMEN1MAPTALDH1A1
Hydrochloric Acid SCHEMBL21645395 0.80 GAA (0.44) CYP1A2KMT2AMEN1MAPTALDH1A1
SCHEMBL8397397 0.80 HSD17B10 (0.56) CYP1A2HSD17B10SIGMAR1GRIN2DGRIN3B
SCHEMBL13302660 0.80 NPSR1 (0.57) CYP1A2HSD17B10KMT2AMEN1MAPT
SCHEMBL14868738 0.80 HSD17B10 (0.49) CYP1A2HSD17B10SIGMAR1GRIN2DGRIN3B
SCHEMBL1229884 0.79 HTR3E (0.54) HSD17B10KMT2AMEN1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110615886-A Biguanide derivative antibacterial epoxy resin curing agent and preparation method thereof 哈尔滨工程大学 2019-12-27 CN claimed
EP-4180482-B1 MOISTURE-CURABLE COMPOSITION NITTO KASEI CO LTD (JP) 2025-12-03 EP disclosed
US-12479869-B2 Curing catalyst used for curing of polymer, method for producing same, moisture-curable composition, and method for producing cured product NITTO KASEI CO., LTD. (JP) 2025-11-25 US disclosed
EP-4174053-B1 CURING CATALYST USED FOR CURING OF POLYMER, METHOD FOR PRODUCING SAME, MOISTURE-CURABLE COMPOSITION, AND METHOD FOR PRODUCING CURED PRODUCT NITTO KASEI CO LTD (JP) 2025-11-19 EP disclosed
EP-4569023-A1 COMBINATION OF CATALYTIC COMPONENTS PolyU GmbH (DE) 2025-06-18 EP disclosed
US-12264275-B2 Treatment liquid FUJIFILM CORPORATION (JP) 2025-04-01 US disclosed
CN-118931672-A Treatment liquid, kit, method for producing treatment liquid, method for cleaning substrate, and method for treating substrate 富士胶片株式会社 2024-11-12 CN disclosed
CN-118931673-A Treatment liquid, kit, method for producing treatment liquid, method for cleaning substrate, and method for treating substrate 富士胶片株式会社 2024-11-12 CN disclosed
CN-115516041-B Curing catalyst for curing polymer, method for producing same, moisture-curable composition, and method for producing cured product 日东化成株式会社 2024-06-28 CN disclosed
WO-2024033348-A1 COMBINATION OF CATALYTIC COMPONENTS POLYU GMBH (DE) 2024-02-15 WO disclosed
US-8796338-B2 Biguanide compositions and methods of treating metabolic disorders ELCELYX THERAPEUTICS, INC (US) 2014-08-05 US disclosed
US-8796338-B2 Biguanide compositions and methods of treating metabolic disorders ELCELYX THERAPEUTICS, INC (US) 2014-08-05 US disclosed
EP-2338938-B1 CURABLE COMPOSITION AND CURED PRODUCT THEREOF KANEKA CORP (JP) 2013-07-31 EP disclosed
WO-2013103384-A1 BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS ELCELYX THERAPEUTICS, INC. (US) 2013-07-11 WO disclosed
US-20130095140-A1 Biguanide Compositions and Methods of Treating Metabolic Disorders ELCELYX THERAPEUTICS, INC. (US) 2013-04-18 US disclosed
US-20130095140-A1 Biguanide Compositions and Methods of Treating Metabolic Disorders ELCELYX THERAPEUTICS, INC. (US) 2013-04-18 US disclosed
EP-2388297-A1 CURABLE COMPOSITION AND CURED OBJECT FORMED THEREFROM Kaneka Corporation (JP) 2011-11-23 EP disclosed
US-20110237723-A1 CURABLE COMPOSITION AND CURED PRODUCT THEREOF KANEKA CORPORATION (JP) 2011-09-29 US disclosed
EP-2338938-A1 CURABLE COMPOSITION AND CURED PRODUCT THEREOF Kaneka Corporation (JP) 2011-06-29 EP disclosed
EP-2267083-A1 CURABLE COMPOSITION AND CURED MATERIAL Kaneka Corporation (JP) 2010-12-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12479869-B2 Curing catalyst used for curing of polymer, method for producing same, moisture-curable composition, and method for producing cured product KDM2B, SETDB1, ASH2L CYP1A2 512/4885HSD17B10 2247/4885SIGMAR1 3942/4885
US-20130095140-A1 Biguanide Compositions and Methods of Treating Metabolic Disorders SLC5A2, SLC5A1, GPR119 CYP1A2 537/4885HSD17B10 269/4885SIGMAR1 3853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.